Title : Pioneering D-MAVS: Designable multi-antivirals that transform how antivirals are created, developed, and used
Abstract:
Decoy Therapeutics is a biotech company pioneering Designable Multi-Antivirals (D-MAVs™) to redefine how viral disease is treated and understood. By harnessing our proprietary IMP³ACT platform, which integrates AI-enabled design with rapid synthesis, we develop adaptable peptide antivirals that target shared viral mechanisms rather than individual pathogens. Decoy is building toward a future where a single, affordable drug can protect many people against multiple viruses, moving faster into the clinic to address the persistent health and societal disruptions caused by viral infections. Our lead program offers a self-administered, intranasally delivered pan-coronavirus fusion inhibitor that exhibits broad, potent antiviral activity, both in the prophylactic and post-exposure dosing paradigms. Pharmacokinetic modelling demonstrates multiday protection, offering a strategic shift from reactive daily dosing to a more robust, durable multi-day antiviral intervention. Decoy’s approach is applicable across multiple viral families and has the potential to redefine next-generation antiviral protection while expanding global access to broad, effective therapies.
